Pom Wonderful LLC v. Coca-Cola Co.
679 F.3d 1170
9th Cir.2012Background
- Pom Wonderful LLC sues Coca-Cola over Coca-Cola's Pomegranate Blueberry juice label/name.
- Product labeling features a flavor-name that Pom asserts misleads that the juice is primarily pomegranate/blueberry.
- FDCA governs misbranding; FDA regulations address naming and labeling of juice beverages.
- District court held name/labeling claims barred by FDCA, allowed other Lanham Act claims to proceed, and preemption of state claims; discovery followed.
- After amended pleading, district court allowed discovery on labeling vs. advertising; summary judgment later barred naming/labeling claims but found standing issues with state-law claims.
- This appeal concerns whether the FDCA bars Pom's Lanham Act claim, standing to sue under UCL/FAL, and preemption of Pom's state-law claims.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| FDCA bars Lanham Act claim over naming and labeling | Pom argues FDA regulations do not authorize Coca-Cola's name/labeling | Coca-Cola relied on FDA rules permitting such naming/labeling | FDCA bars naming/labeling Lanham Act claim |
| Whether Lanham Act claims may proceed without FDA interpretation | Pom can pursue non-FDCA-interpretive advertising claims | Lanham Act claims cannot undermine FDA authority | Lanham Act claim barred where it would require interpreting FDA regulations |
| Standing to pursue UCL and FAL claims | Pom has injury and seeks restitution | Pom lacks lost money or property to support standing | Remand to resolve standing consistent with Kwikset/Clayworth |
| Whether state-law claims are expressly preempted by FDCA | State claims independent of FDA labeling rules | FDCA preempts nonidentical state requirements | Preemption issue requires district court reconsideration on remand |
| Impact of FDA/FDCA on overall labeling-deception analysis | FDA not addressing deception here | FDA regulations control labeling standards | Court respects FDA judgments; private Lanham Act relief on labeling is limited |
Key Cases Cited
- PhotoMedex, Inc. v. Irwin, 601 F.3d 919 (9th Cir. 2010) (Lanham Act claims barred where they would usurp FDA authority)
- Schering-Plough Healthcare Prods., Inc. v. Schwarz Pharma, Inc., 586 F.3d 500 (7th Cir. 2009) (balance statutes where FDA regulates labeling)
- Mylan Labs., Inc. v. Matkari, 7 F.3d 1130 (4th Cir. 1993) (Lanham Act cannot enforce FDCA or require FDA interpretation)
- Sandoz Pharms. Corp. v. Richardson-Vicks, Inc., 902 F.2d 222 (3d Cir. 1990) (private Lanham Act claims should not interpret ambiguous FDA regs)
- PhotoMedex, Inc. v. Irwin, 601 F.3d 919 (9th Cir. 2010) (presumption against private litigation undermining FDA judgments)
- Kwikset Corp. v. Superior Ct., 51 Cal.4th 310 (Cal. 2011) (standing under UCL; not dependent on restitution eligibility)
- Clayworth v. Pfizer, Inc., 49 Cal.4th 758 (Cal. 2010) (standing under FAL identical to UCL standing)